Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Trials

Background:

• Antiplatelet drug therapy is crucial for managing cardiovascular disease and coronary artery disease.
• Despite benefits, many patients experience recurrent adverse cardiovascular events due to nonresponsiveness to antiplatelet agents.
• Variability in responsiveness is linked to pharmacological and pharmacokinetic factors, including genetics and drug interactions.

Purpose of the Study:

• To review the current understanding of antiplatelet drug nonresponsiveness in cardiovascular disease.
• To highlight the association between nonresponsiveness and adverse clinical outcomes.
• To identify the need for further research and standardized trials to establish effective therapeutic strategies.

Main Methods:

• Review of large clinical trials and observational studies on antiplatelet therapy.
• Analysis of factors contributing to variability in antiplatelet drug responsiveness.
• Examination of recent randomized clinical trials investigating dosing strategies.

Main Results:

• Observational studies consistently link antiplatelet drug nonresponsiveness to adverse clinical outcomes.
• Recent randomized trials suggest increased antiplatelet drug dosing may reduce adverse events.
• Limitations in existing studies include varied dosing, laboratory assessments, and interindividual responses.

Conclusions:

• Antiplatelet drug nonresponsiveness remains a significant clinical challenge in cardiovascular disease management.
• Standardized, large-scale clinical trials are essential to confirm the link between nonresponsiveness and outcomes.
• Developing strategies to overcome blunted antiplatelet effects is critical for improving patient care.